KRYS241220P105000
- 9.29
- 0.000.00%
Krystal Biotech Newsroom
Krystal Biotech Is Maintained at Neutral by Citigroup
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $206 to $221
Krystal Biotech's Strong Financial Performance and Strategic Advancements Drive Buy Rating
Stifel Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $220
Stifel Nicolaus Remains a Buy on Krystal Biotech (KRYS)
Krystal Biotech Analyst Ratings
Stifel Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $204
TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $208
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $221
Krystal Biotech Analyst Ratings
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $221
Buy Rating Affirmed for Krystal Biotech Following Promising KB301 Study Results
Stifel Maintains Krystal Biotech(KRYS.US) With Buy Rating
Stifel Nicolaus Keeps Their Buy Rating on Krystal Biotech (KRYS)
Evercore ISI Lifts Price Target on Krystal Biotech to $206 From $201, Keeps Outperform Rating
Krystal Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Krystal Biotech (KRYS) and InflaRx (IFRX)
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $200 to $208
Chardan Research Adjusts Price Target on Krystal Biotech to $208 From $153, Maintains Buy Rating
Buy Rating Affirmed for Krystal Biotech Amid Strong Financial Performance and Market Growth Potential